The short version of gastric juice protein fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-20. Anything still debated is marked as such rather than presented as settled.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
The toxic action of mHTT may manifest and produce the HD pathology through multiple cellular changes. In its mutant (polyglutamine expanded) form, the protein is more prone to cleavage that creates shorter fragments containing the polyglutamine expansion. These protein fragments have a propensity to undergo misfolding and aggregation, yielding fibrillar aggregates in which non-native polyglutamine β-strands from multiple proteins are bonded together by hydrogen bonds. These aggregates share the same fundamental cross-beta amyloid architecture seen in other protein deposition diseases. The aggregates are covered on their surface with a 'fuzzy coat' that contains non-polyglutamine parts of the protein, as illustrated in a published structural model shown above. Over time, the aggregates accumulate to form inclusion bodies within cells, ultimately interfering with neuronal function. Inclusion bodies have been found in both the cell nucleus and cytoplasm. Inclusion bodies in cells of the brain are one of the earliest pathological changes, and some experiments have found that they can be toxic for the cell, but other experiments have shown that they may form as part of the body's defense mechanism and help protect cells. Several pathways by which mHTT may cause cell death have been identified.
These include defence cells and proteins such as Neutrophils, Antibodies and Complement, and various plasma protein. With the outflow of the Gingival Crevicular Fluid (GCF) into the gingival sulcus, at a rate of approximately 0.2ul per hour, that significantly increases with the presence of periodontal disease, this produces a “washing effect” that aids in preventing bacterial invasion.
=== Chemical === Different chemical procedures for the conversion into final products or the removal of pollutants are used for the safe disposal of contaminants. Pre-chlorination for algae control and arresting biological growth. Aeration along with pre-chlorination for removal of dissolved iron when present with relatively small amounts of manganese. Disinfection for killing bacteria, viruses and other pathogens, using chlorine, ozone and ultra-violet light.
Rilwanu Lukman- former Minister of Petroleum Resources and Mines, Power, Steel; and former secretary general OPEC. Maikanti Baru - engineer, former GMD Of NNPC Limited. Mohammed Bello-Koko - former managing director of the Nigerian Ports Authority Muhammed Babandede - former Comptroller General (CG) of the Nigeria Immigration Service NIS. Ahmad Salihijo Ahmad - former managing director of Nigerian Rural Electrification Agency. M.T. Usman - former permanent secretary ministry of Works. Abubakar Dantsoho - Managing Director of the Nigerian Ports Authority (NPA). Hamman Bello - former Comptroller- General Of Nigeria Customs Service. Musa Yar'Adua - Minister of Lagos Affairs 1960 -1966, Matawalle of the Katsina Emirate. Muhammadu Ribadu – first minister of defence after independence, founder of the Nigerian Defence Academy. Mansur Muhtar – economist, former Nigerian Federal minister of finance (2008 -2010), former director World Bank, presently vice chairman, Islamic Development Bank. Tajudeen Abbas - Speaker of the House of Representatives of Nigeria. Abubakar Olusola Saraki – (Fulani/Yoruba); former president of the Senate. Gbemisola Ruqayyah Saraki – (Fulani/Yoruba); former Senator Kwara Central, current Minister of State. Transportation of the Federal Republic of Nigeria. Nigeria. Aisha Dikko - former attorney general, commissioner of Justice Kaduna. Bukola Saraki – (Fulani/Yoruba); former president of the Nigerian Senate; former Governor of Kwara State and former Senator Kwara Central, Nigeria. Captain Muhammad Bala Shagari – politician, former Nigerian Army officer.
to be undetectable using standard 1970s and 1980s NATO chemical detection equipment; to defeat NATO chemical protective gear; to be safer to handle; and to circumvent the Chemical Weapons Convention list of controlled precursors, classes of chemical and physical form. Some of these agents are binary weapons, in which precursors for the nerve agents are mixed in a munition to produce the agent just prior to its use. The precursors are generally significantly less hazardous than the agents themselves, so this technique makes handling and transporting the munitions a great deal simpler. Additionally, precursors to the agents are usually much easier to stabilise than the agents themselves, so this technique also makes it possible to increase the shelf life of the agents. This has the disadvantage that careless preparation may produce a non-optimal agent. During the 1980s and 1990s, binary versions of several Soviet agents were developed and are designated as "Novichok" agents.
Sources: en.wikipedia.org
==== Digital wholesale and B2B platforms ==== Wholesale is increasingly supported by e-procurement, B2B marketplaces, and automated order-to-cash processes (catalogs, electronic orders, invoicing, and payments). UNCTAD reports that "business e-commerce" sales grew strongly from 2016 to 2022 (with trillions of dollars in value across measured economies), reflecting the growing role of digital channels in business purchasing and selling. Artificial Intelligence (AI) has been used in B2B sourcing and procurement more recently but can still be considered in its infancy. When AI is used to address business issues, the main features of AI include increasing human efficiency and automation.
=== Past === Nicaragua (1985–1990 for aggressive activities in Central America) South Africa (1985–1991 for maintaining apartheid) Libya (1986–2004 for sponsoring terrorism) Panama (1988–1990 against the Manuel Noriega government) Kuwait (1990–1991, while occupied by Iraq) Iraq (1990–2004 for invading Kuwait) Haiti (1991–1994 for the 1991 Haitian coup d'état) Serbia and Montenegro (1992–2003 for sponsoring Serb nationalist groups) UNITA (1993–2003 for interfering with UN peacekeeping efforts) Myanmar (1997–2016 against the policies of the military government) Afghanistan (1999–2002 for harboring al-Qaeda) Russia (2000–2012 to support the Megatons to Megawatts Program) Sierra Leone (2001–2004 for human rights violations) Liberia (2001–2015 directed against President Charles G. Taylor) Zimbabwe (2003–2024 against the ZANU–PF government) Syria (2004–2025 against the Bashar al-Assad government) Côte d'Ivoire (2006–2016 regarding the First Ivorian Civil War) International Criminal Court (2020–2021 for investigating actions by United States personnel in Afghanistan) West Bank settlers (2024–2025 for violence against Palestinians)
Chinese traditional medicine uses the oil of crocodiles for other conditions such as bronchitis, allergy, skin problems, high blood pressure, and cancer. Crocodile oil is also prescribed to treat burns, skin ulcers and cancer, coughs, and asthma in Madagascar. There is also evidence of crocodile oil being used traditionally in South Africa for skin condition treatments for eczema and rashes and for promoting wound healing. Crocodile oil is used in Mexico for treatment of illnesses such as asthma, emphysema, and influenza.
==== United States ==== In April 2020, The Hill reported that markets selling live animals were still operating in the United States and that animal rights activists were calling for the closure of such markets, in addition to their existing calls to close factory farms. Fresh food markets were common in New York City until refrigeration became commonplace in the 20th century. From the 1990s to 2020, the number of live animal markets in New York City nearly doubled. As of 2020, there are more than 80 markets in New York City that stock live animals and slaughter them on-demand for customers. They are mostly poultry markets located in outer-borough immigrant communities where they are culturally significant and pose low public health risks relative to wildlife markets and other types of exotic markets.
A fluorescence microscopy-based assay reveals that the relative number of SeV virions bound to the receptor can be defined as 0.5 for GM3, as 1 for GD1a, and as 2 for Gq1b. The structures of some of these receptors are available for visualization through SugarBindDB – a resource of glycan-mediated host–pathogen interactions. Others are available through KEGG Glycan Database, PubChem compound database, and TOXNET database (toxicology data network) of US National Library of Medicine.
Sources: en.wikipedia.org
The pathologist's interpretation of a biopsy is critical to establishing the diagnosis of a benign or malignant tumor, and can differentiate between different types and grades of cancer, as well as determining the activity of specific molecular pathways in the tumor. Surgical resection specimens are obtained by the therapeutic surgical removal of an entire diseased area or organ (and occasionally multiple organs). These procedures are often intended as definitive surgical treatment of a disease in which the diagnosis is already known or strongly suspected, but pathological analysis of these specimens remains important in confirming the previous diagnosis.
=== Sonic spray ionization === Sonic spray ionization is method for creating ions from a liquid solution, for example, a mixture of methanol and water. A pneumatic nebulizer is used to turn the solution into a supersonic spray of small droplets. Ions are formed when the solvent evaporates and the statistically unbalanced charge distribution on the droplets leads to a net charge and complete desolvation results in the formation of ions. Sonic spray ionization is used to analyze small organic molecules and drugs and can analyze large molecules when an electric field is applied to the capillary to help increase the charge density and generate multiple charged ions of proteins. Sonic spray ionization has been coupled with high performance liquid chromatography for the analysis of drugs. Oligonucleotides have been studied with this method. SSI has been used in a manner similar to desorption electrospray ionization for ambient ionization and has been coupled with thin-layer chromatography in this manner.
== History == In the 1930s, hydrocortisone was found by biochemist Edward C. Kendall and rheumatologist Philip S. Hench, who were both Nobel laureates. When they were investigating therapies for rheumatoid arthritis, they discovered that female patients of the disease would experience an alleviation of their condition if they were pregnant at the same time. It was also found that patients suffering from both rheumatoid arthritis and jaundice would have fewer symptoms associated with rheumatoid arthritis. Following this finding, they extracted different hormones from the adrenal cortex of cows in search of a suitable drug. They first identified cortisone to be one of the possible drugs, and further research led them to discover an effective drug for human dermal problems, which was hydrocortisone. After the discovery of hydrocortisone, the earliest application of hydrocortisone as a topical form in humans was recorded in 1952. Its successful utilization facilitated more research on topical corticosteroids, which helped the development of similar drugs with higher activity.
=== Radiography === Radiographs of the abdomen commonly show hepatomegaly. Hepatomegaly is not exclusive to hypersomatotropism and is seen in diabetic cats without hypersomatotropism. Other possible findings are renomegaly and on rare occasions splenomegaly. Thoracic radiographs can reveal cardiomegaly, pulmonary oedema, and, if affected by congestive heart failure, pleural effusion. Radiographs of bones—including the skull and spine—may reveal: increase of soft tissue around the oropharynx, mandible enlargement, hyperostosis of the calvarium and nasal bone, degenerative arthropathy of the joints, and spondylosis deformans.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.